The 20 Best Medulloblastoma Doctors Near Me in District of Columbia, US

Roger Packer is a Pediatrics provider practicing medicine in Washington, Washington, D.c.. Dr. Packer is rated as an Elite provider by MediFind in the treatment of Medulloblastoma. He is also highly rated in 30 other conditions, according to our data. His clinical expertise encompasses Brain Tumor, Diffuse Midline Glioma H3 K27M-Mutant, Medulloblastoma, and Gliomatosis Cerebri.

Brian R. Rood, MD, is the director of clinical neuro-oncology and the medical director of the Brain Tumor Institute at Children's National Hospital. Dr. Rood is also a principal investigator in the Center for Cancer and Immunology Research at Children's National Research Institute and a professor of pediatrics at the George Washington University School of Medicine and Health Sciences and adjunct professor at the Fralin Biomedical Research Institute at Virginia Tech. He received a Bachelor of Arts in English Literature from The Pennsylvania State University and completed medical school at Jefferson Medical College. He completed his pediatric residency training at the University of Vermont. Dr. Rood received his pediatric hematology/oncology training at Children's National. He joined the faculty of Children’s National in 2002 after completing a fellowship in pediatric hematology/oncology, as well as a research fellowship in the molecular biology of brain tumors, both at Children’s National and Children’s National Research Institute. Currently, Dr. Rood’s research focuses on the application of proteomics in cancer biology investigation, neoantigen identification and biomarker development. He has also been studying the contribution of germline microsatellite genotypes to pediatric brain tumor predisposition. He currently serves as the executive co-chair of the Children’s Brain Tumor Network, an international consortium of 28 institutions that maintains the world’s largest pediatric brain tumor tissue and data repository, which are freely provided to the research community to support the development of groundbreaking clinical trials through data-driven precision medicine. Dr. Rood has two children. His favorite pastimes include designing and building furniture, sailing, reading, and playing the mandolin. Dr. Rood is rated as a Distinguished provider by MediFind in the treatment of Medulloblastoma. He is also highly rated in 4 other conditions, according to our data. His clinical expertise encompasses Medulloblastoma, Embryonal Tumor with Multilayered Rosettes, Glioma, and Diffuse Midline Glioma H3 K27M-Mutant. Dr. Rood is board certified in Pediatric Hematology-Oncology: American Board Of Pediatrics, 2002 and Pediatrics: American Board Of Pediatrics, 1998.

Dr. Solmaz Sahebjam is a medical oncologist and an associate professor of oncology at Johns Hopkins University School of Medicine. Her expertise is in primary and metastatic brain tumors, breast cancer, and the development of new drugs for cancer. She earned her medical degree from Iran University of Medical Sciences, followed by a post-doctoral research fellowship at Shriners Hospital, McGill University in Montreal. Dr. Sahebjam completed residency training in internal medicine at Saint Vincent Hospital, followed by a fellowship in internal medicine at the University of Ottawa in Canada. She continued her training with a residency in medical oncology at McGill University in Canada followed by a fellowship in early-phase drug development, breast oncology, and neurooncology at Princess Margaret Hospital, University of Toronto in Canada. Dr. Sahebjam’s research is focused on the development of novel therapeutic regimens for the treatment of cancer including breast and central nervous system malignancies. Over the years, she has led and contributed to numerous clinical trials some of which have resulted in new treatment options for patients with cancer. Dr. Sahebjam is rated as an Advanced provider by MediFind in the treatment of Medulloblastoma. She is also highly rated in 17 other conditions, according to our data. Her clinical expertise encompasses Glioma, Brain Tumor, Glioblastoma, Astrocytoma, and Awake Craniotomy. Dr. Sahebjam is board certified in American Board Of Internal Medicine.

Matthew Ladra, M.D., M.P.H., leads the dedicated pediatric team for the Johns Hopkins Proton Therapy Center and is the director of pediatric radiation oncology for the Johns Hopkins Kimmel Cancer Center, a clinical collaboration with Children’s National Hospital, where Dr. Ladra serves as faculty in the department of pediatric oncology. He is also an assistant professor of radiation oncology and molecular radiation sciences at the Johns Hopkins School of Medicine. Listen Dr. Ladra's Cancer Matters podcast episode to learn more about his work. Previously, Dr. Ladra served as the director of pediatric radiation at the Provision Center for Proton Therapy in Tennessee. He also completed a 2-year fellowship in pediatric proton therapy at the Massachusetts General Hospital’s Francis H. Burr Proton Center. Dr. Ladra is one of a handful of radiation oncologists whose research and clinical efforts focus exclusively on pediatric patients. He is frequently invited to speak on pediatric radiation oncology topics internationally and across the U.S. and has published extensively on the subject through original research book chapters and review articles. Dr. Ladra’s research efforts focus mainly on pediatric rhabdomyosarcoma treatment, early phase clinical trials involving radiation and non-chemotherapeutic agents, and reducing neurocognitive toxicity for pediatric brain tumor patients. LinkedIn https://www.linkedin.com/in/matthew-ladra-3094a316. Dr. Ladra is rated as an Experienced provider by MediFind in the treatment of Medulloblastoma. He is also highly rated in 7 other conditions, according to our data. His clinical expertise encompasses Rhabdomyosarcoma, Muscle Invasive Bladder Cancer, Adult Soft Tissue Sarcoma, and Ependymoma. Dr. Ladra is board certified in American Board Of Radiology.

"Eugene (Gene) Hwang, MD, is chief of the Division of Oncology at Children’s National Hospital in Washington, D.C. He is also part of the Children's National Hospital pediatric neuro-oncology team, focusing on treating children with brain tumors. Dr. Hwang has developed and led many novel early phase therapeutic clinical trials with a focus on immunotherapeutic trials, and he also leads trials focused on gene therapy and new, targeted agents. He is the site Principal Investigator of the Pediatric Brain Tumor Consortium, where he is the co-chair of the Immunotherapy Working Group. He serves on grant review committees and on the scientific advisory boards of several large foundations. For each patient, Dr. Hwang carefully considers the best possible options for treatment, trying new, cutting edge treatments coupled with the best available known therapies. Dr. Hwang is not only dedicated to finding a cure for cancer, but also to making the current treatments as safe as possible for children: ""We often focus on curing the children - that's the number one goal - but we also need to pay attention to the toxicity of these treatments, and what quality of life the children will have after treatment."" Dr. Hwang is involved in several international efforts to study how to best mitigate treatment side effects. In the meantime, Dr. Hwang makes sure he is doing everything he can to combat pain, dizziness, fatigue and other common side effects of cancer treatments by leveraging the multidisciplinary team approach of Children's National. He sees this as something the organization does exceptionally well, and thinks that having so many people focus on a single patient in a single visit is crucial to well-being during cancer treatment.". Dr. Hwang is rated as an Advanced provider by MediFind in the treatment of Medulloblastoma. He is also highly rated in 8 other conditions, according to our data. His clinical expertise encompasses Pineocytoma, Glioma, Medulloblastoma, and Pineoblastoma. Dr. Hwang is board certified in Pediatric Hematology-Oncology: American Board Of Pediatrics, 2009 and Pediatrics: American Board Of Pediatrics, 2005.

Lindsay Kilburn, MD, comes to Children's National Hospital from Texas Children’s Hospital in Houston, TX, where she was an assistant professor of pediatrics in the neuro-oncology and pharmacology programs. Dr. Kilburn graduated with a degree in Environmental Sciences from the University of Virginia. After graduating from Eastern Virginia Medical School, she completed her pediatric training at the Children’s Hospital of The King’s Daughters in Norfolk, VA, and her hematology/oncology fellowship at Texas Children’s Hospital/Baylor College of Medicine in Houston, TX. She also has received training in pharmacology from both Thomas Jefferson University in Philadelphia and the Baylor College of Medicine in Houston. Dr. Kilburn is an associate professor, pediatrics at George Washington University School of Medicine. Her research focuses on the development and evaluation of new therapeutic agents for children with pediatric brain tumors through clinical trials. She is committed to the improvement of palliative and supportive care. Dr. Kilburn grew up outside of Philadelphia and is married with young twins. Outside of work, she enjoys sailing, hiking, and traveling with her family. Dr. Kilburn is rated as an Advanced provider by MediFind in the treatment of Medulloblastoma. She is also highly rated in 9 other conditions, according to our data. Her clinical expertise encompasses Diffuse Midline Glioma H3 K27M-Mutant, Brain Stem Cancer, Glioma, and Optic Glioma. Dr. Kilburn is board certified in Pediatric Hematology-Oncology: American Board Of Pediatrics, 2009 and Pediatrics: American Board Of Pediatrics, 2004.

Jeffrey Dome, MD, PhD, is senior vice president of the Cancer and Blood Disorders Center at Children’s National Hospital in Washington, D.C. He is professor of pediatrics at the George Washington University School of Medicine and Health Sciences and the Thomas Willson and Lenore Williams McKnew professor of pediatric oncology. Dr. Dome received his medical degree from the University of Pennsylvania School of Medicine and PhD degree in medicine from Erasmus University in Rotterdam. He completed a residency in pediatrics at Yale-New Haven Hospital and completed a fellowship in pediatric hematology/oncology at Johns Hopkins Hospital. After fellowship, Dr. Dome was a faculty member at St. Jude Children’s Research Hospital before joining Children’s National in 2006. Dr. Dome is an internationally recognized expert on pediatric solid tumors, with an emphasis on kidney tumors and sarcomas. He chaired the Children’s Oncology Group (COG) Renal Tumor Committee for more than a decade. He is presently on the Scientific Council of the COG, the editorial board of Pediatric Blood and Cancer, and is past chair of the American Board of Pediatrics Subboard of Hematology/Oncology. Dr. Dome serves on numerous medical advisory boards for cancer foundations and currently is the North American Continental President of the International Society of Pediatric Oncology (SIOP). He has authored more than 200 articles, books, letters and chapters on pediatric cancer. Dr. Dome is rated as an Advanced provider by MediFind in the treatment of Medulloblastoma. He is also highly rated in 17 other conditions, according to our data. His clinical expertise encompasses Rhabdoid Tumor, Denys-Drash Syndrome (DDS), Adult Soft Tissue Sarcoma, Nephrectomy, and Bone Marrow Aspiration. Dr. Dome is board certified in Pediatric Hematology-Oncology: American Board Of Pediatrics, 1998.

Luca Szalontay is a Pediatric Hematologist Oncology provider practicing medicine in Washington, Washington, D.c.. She has been practicing medicine for over 17 years. Dr. Szalontay is rated as an Experienced provider by MediFind in the treatment of Medulloblastoma. She is also highly rated in 2 other conditions, according to our data. Her clinical expertise encompasses Glioma, Diffuse Midline Glioma H3 K27M-Mutant, Medulloblastoma, and Brain Stem Cancer. Dr. Szalontay is board certified in Pediatric Hematology-Oncology: American Board Of Pediatrics, 2021 and Pediatrics: American Board Of Pediatrics, 2015.

Robert Keating, MD, is currently a McCullough distinguished professor, interim senior vice president, Neuroscience and Behavioral Medicine Center and chief of Neurosurgery at Children’s National Hospital. A graduate of Georgetown University Medical School, he completed a neurosurgery residency and fellowship in pediatric neurosurgery/craniofacial surgery at the Albert Einstein and Montefiore Medical Center in the Bronx, NY. Following his training, Dr. Keating served in the U.S. Navy and was stationed at the Oakland Naval Hospital serving as the chief from 1991-1994. After his time in the Navy, he returned to the Bronx where he was on staff at Montefiore Medical Center as well as the Bronx Municipal Hospital Center for two years before coming back to Washington, D.C., in 1996 to join the faculty at Children’s National Dr. Keating's past appointments include the president of the medical staff at Children’s National, as well as head of credentials. He currently maintains a busy practice of pediatric neurosurgery, with an emphasis on tumors, Chiari malformations, craniofacial reconstruction, spinal dysraphism, spasticity and brachial plexus surgery. As a member of the American Society of Pediatric Neurosurgery and International Society of Pediatric Neurosurgery, he has published and presented extensively in the field. His publications include the previous texts, “An Atlas of Orbitocranial Surgery” and “Tumors of the Pediatric Nervous System” (2nd edition published in 2013), with current work on Neurosurgical Operative Atlas, (2nd ed. Goodrich JT, and Keating RF, Thieme) due for publication in 2018. He is also chair, medical advisory committee on the Board of the American Syringomyelia Alliance Project as well as a founding member of the Posterior Fossa Society and maintains long-standing membership in the CNS, AANS, ASPN and ISPN. Dr. Keating is rated as an Experienced provider by MediFind in the treatment of Medulloblastoma. He is also highly rated in 22 other conditions, according to our data. His clinical expertise encompasses Craniosynostosis, Metopic Ridge, Chiari Malformation Type 1, Posterior Fossa Decompression, and Craniectomy. Dr. Keating is board certified in Neurological Surgery: American Board Of Neurological Surgery, 2000 and Neurological Surgery: American Board Of Neurological Surgery, 1993.

Adriana Sheridan is a Pediatrics provider practicing medicine in Washington, Washington, D.c.. She has been practicing medicine for over 20 years. Dr. Sheridan is rated as an Experienced provider by MediFind in the treatment of Medulloblastoma. Her clinical expertise encompasses Diffuse Midline Glioma H3 K27M-Mutant, Medulloblastoma, Pediatric Low-Grade Glioma (pLGG), and Glioma. Dr. Sheridan is board certified in Pediatrics: American Board Of Pediatrics, 2024, Pediatric Hematology-Oncology: American Board Of Pediatrics, 2021, and The Royal College Of Physicians And Surgeons Of Canada, 2015.

Elizabeth Wells, MD, MHS, is the executive vice president, chief clinical officer and physician-in-chief. Dr. Wells has executive oversight for ensuring optimal delivery of clinical care while fostering an environment that supports research, education and operational excellence. In her previous role as senior vice president of the Neuroscience and Behavioral Medicine Center, she grew programmatic and research impact across multidisciplinary destination programs, quality and safety, and patient experience across the care continuum for brain injury and disorders, mental and behavioral health, and neurodevelopmental conditions. Dr. Wells previously held leadership roles in clinical research administration and served as president of the Children’s National Medical Staff from 2020 to 2021 and Credentials Committee chair from 2022 to 2023. Dr. Wells is a graduate of Harvard University and the George Washington University School of Medicine and Health Sciences. She holds a master’s degree in health science from the NIH/Duke Clinical Research Training Program. She completed pediatrics and neurology training at Children’s National and served as a pediatric neurologist within the Brain Tumor Institute and the Division of Neurology, rising to the rank of professor in Pediatrics, Neurology and Rehabilitation Medicine. Dr. Wells serves on the board for the Pediatric Specialists of Virginia, is past president of the Washington Clinico-Pathological Society and a graduate of Leadership Greater Washington's 2022 Signature class. In her new leadership role, Dr. Wells provides strategic, financial and administrative leadership across five centers of excellence, general pediatrics and multiple institutes, including about 3,000 employees, to advance high-quality outcomes and integrated services. Dr. Wells is rated as an Experienced provider by MediFind in the treatment of Medulloblastoma. Her clinical expertise encompasses West Syndrome, Multisystem Inflammatory Syndrome in Children (MIS-C), Medulloblastoma, and Anti-NMDA Receptor Encephalitis. Dr. Wells is board certified in American Board Of Psychiatry And Neurology, 2011.

Catherine Bollard is a Pediatrics provider practicing medicine in Washington, Washington, D.c.. Dr. Bollard is rated as an Experienced provider by MediFind in the treatment of Medulloblastoma. She is also highly rated in 7 other conditions, according to our data. Her clinical expertise encompasses Hodgkin Lymphoma, Graft Versus Host Disease (GvHD), Leukemia, Acute Lymphoblastic Leukemia (ALL), and Bone Marrow Transplant.

Hannah Kinoshita, MD, is an oncologist in the Division of Oncology in the Center for Cancer and Blood Disorders. Her research interests include cellular immunotherapy for high-risk hematologic malignancies. Dr. Kinoshita is rated as an Experienced provider by MediFind in the treatment of Medulloblastoma. Her clinical expertise encompasses Multisystem Inflammatory Syndrome in Children (MIS-C), Acute Lymphoblastic Leukemia (ALL), Leukemia, Medulloblastoma, and Bone Marrow Transplant. Dr. Kinoshita is board certified in Pediatric Hematology-Oncology: American Board Of Pediatrics, 2023 and American Board Of Pediatrics, 2018.

Reuven Schore, MD, is a pediatric oncologist and a member of the Leukemia/Lymphoma Program at Children's National Hospital. Dr. Schore is an associate professor, pediatrics at George Washington University School of Medicine. Dr. Schore is the vice chair for a Children's Oncology Group study investigating intravenous treatments for patients with high-risk acute lymphoblastic leukemia (ALL). Dr. Schore is rated as an Experienced provider by MediFind in the treatment of Medulloblastoma. He is also highly rated in 3 other conditions, according to our data. His clinical expertise encompasses Acute Lymphoblastic Leukemia (ALL), Leukemia, Juvenile Myelomonocytic Leukemia (JMML), and Febrile Neutropenia. Dr. Schore is board certified in Pediatric Hematology-Oncology: American Board Of Pediatrics, 2006 and Pediatrics: American Board Of Pediatrics, 2003.

Holly Meany, MD, is a pediatric oncologist and director of the Solid Tumor Program at Children’s National Hospital. She also serves as an associate professor of pediatrics at George Washington University. Dr. Meany is dedicated to finding better treatments for children with cancer through research and clinical care. Her work focuses on developing new therapies for pediatric solid tumors. She designs and leads early-phase clinical trials to test promising treatments and understand how they work in children. Dr. Meany has played a key role in several national studies, including large trials for neuroblastoma, a type of childhood cancer. She recently led an international study for children with newly diagnosed non-high-risk neuroblastoma and is currently helping to develop the next high-risk neuroblastoma trial, both through the Children’s Oncology Group. Dr. Meany is also exploring innovative approaches like immunotherapy—using the body’s own immune system to fight cancer. She has led international studies using specialized T cells to treat patients with relapsed solid tumors and is now working on combining these novel T cells with CAR T-cell therapy for children with relapsed cancers. In addition to her research, Dr. Meany is passionate about training the next generation of pediatric cancer specialists. As director of the Pediatric Hematology-Oncology Fellowship Program at Children’s National, she mentors and supports future leaders in the field. Dr. Meany is rated as an Experienced provider by MediFind in the treatment of Medulloblastoma. She is also highly rated in 3 other conditions, according to our data. Her clinical expertise encompasses Neuroblastoma, Hereditary Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, Osteosarcoma, and Mastoidectomy. Dr. Meany is board certified in Pediatric Hematology-Oncology: American Board Of Pediatrics, 2006 and Pediatrics: American Board Of Pediatrics, 2003.

Jennifer Levine is a Pediatric Hematologist Oncology provider practicing medicine in Washington, Washington, D.c.. She has been practicing medicine for over 27 years. Dr. Levine is rated as an Experienced provider by MediFind in the treatment of Medulloblastoma. Her clinical expertise encompasses Acute Lymphoblastic Leukemia (ALL), Malignant Peripheral Nerve Sheath Tumor, Febrile Neutropenia, and Medulloblastoma. Dr. Levine is board certified in American Board Of Pediatrics, 2006 and American Board Of Pediatrics, 2003.

Anatoly Dritschilo is a Radiation Oncologist practicing medicine in Washington, Washington, D.c.. Dr. Dritschilo is rated as an Experienced provider by MediFind in the treatment of Medulloblastoma. He is also highly rated in 2 other conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Familial Prostate Cancer, Medulloblastoma, Embryonal Tumor with Multilayered Rosettes, and Liver Embolization.

Jeffrey Toretsky is a Hematologist and an Oncologist practicing medicine in Washington, Washington, D.c.. Dr. Toretsky is rated as an Experienced provider by MediFind in the treatment of Medulloblastoma. He is also highly rated in 6 other conditions, according to our data. His clinical expertise encompasses Ewing Sarcoma, Osteosarcoma, Adult Soft Tissue Sarcoma, Rhabdomyosarcoma, and Bone Marrow Aspiration.

Marc Lippman is a Hematologist practicing medicine in Washington, Washington, D.c.. Dr. Lippman is rated as an Experienced provider by MediFind in the treatment of Medulloblastoma. He is also highly rated in 5 other conditions, according to our data. His clinical expertise encompasses Breast Cancer, Paget Disease of the Breast, Inflammatory Breast Cancer, and Angiosarcoma.

Mona Elmacken is a Hematologist and an Oncologist practicing medicine in Washington, Washington, D.c.. Dr. Elmacken is rated as an Experienced provider by MediFind in the treatment of Medulloblastoma. Her clinical expertise encompasses Ewing Sarcoma, Medulloblastoma, Osteosarcoma, Neuroblastoma, and Bone Marrow Transplant.